Letter to the Editor

Willing to Pay for Antiviral Treatment of Hepatitis B Patients

Abstract

Willing to Pay for Antiviral Treatment of Hepa¬titis B Patients

Yuan Y, Iloeje U, Li H, Hay J, Yao GB (2008). Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program. Value Health, 11:S11–22.

Liaw YF, Sung JJ, Chow WC, Farrell G，Lee CZ ,et al. (2004). Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 351:1521–31.

Antonucci G, Mazzotta F, Puoti M, Angeletti C, Girardi E, et al. (2012). Factors associated with access to antiviral treatment in a multicentre cross-sectional study of patients with chronic hepatitis B in Italy. J Viral Hepat, 19: 881–9.

Zhuang H (2010). Standard antiviral treatment of hepatitis B. J Med Res, 39:1-2.

Rasell ME (1995).Cost sharing in health insurance--a reexamination. N Engl J Med, 332:1164–8.

Files
IssueVol 45 No 12 (2016) QRcode
SectionLetter to the Editor
Keywords
No keywords##
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
ZHANG H, HUO M, CHAO J, LIU P. Willing to Pay for Antiviral Treatment of Hepatitis B Patients. Iran J Public Health. 2016;45(12):1660-1661.